← Back to headlines
Vertex Pharmaceuticals Surpasses Citigroup Biotech Forecasts Following Crinetics Acquisition
Vertex's stock climbs after completing its acquisition of Crinetics, positioning the company ahead of analyst predictions and strengthening its pipeline in rare disease treatments.
3 Sept, 17:34 — 3 Sept, 17:34
Sources
Showing 1 of 1 sources
